1 Min Read
April 6 (Reuters) - Myriad Genetics Inc:
* Myriad Genetics and Beigene sign agreement to develop companion diagnostics for use with Beigene's novel parp inhibitor, BGB-290
* Myriad Genetics Inc - specific terms of deal were not disclosed.
* Myriad Genetics-under deal Beigene to use co's mychoice HRD, bracanalysis CDX companion diagnostic tests to support clinical development of BGB-290 Source text for Eikon: Further company coverage: